Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2022 Feb 1;12(1):1996.
doi: 10.1038/s41598-022-05835-2.

Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Affiliations
Published Erratum

Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al. Sci Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The updated meta-analysis of viral clearance of Favipiravir on COVID-19 patients after removal of Dabbous et al. data (Orange diamond: summary of sub groups; Red diamond: summary of total).
Figure 2
Figure 2
The updated meta-analysis of mortality of Favipiravir on COVID-19 patients after removal of Dabbous et al. data (Red diamond: summary of total).

Erratum for

References

    1. Dabbous HM, El-Sayed MH, El Assal G, et al. RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci. Rep. 2021;11:7282. doi: 10.1038/s41598-021-85227-0. - DOI - PMC - PubMed
    1. Dabbous HM, El-Sayed MH, El Assal G, et al. Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci. Rep. 2021;11:18983. doi: 10.1038/s41598-021-98683-5. - DOI - PMC - PubMed

Publication types